CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
MiRacle aims to develop a targeted therapeutic formulation using microRNA to treat head and neck cancer. By combining innovative drug delivery technologies, the project seeks to improve treatment outcomes for patients with advanced stages of this disease.
MiRacle focuses on the development of a therapeutic formulation for the treatment of head and neck cancer.
Head and neck cancer contributes to approximately 5% of all cancers in the Western world.
Unfortunately the majority of H&N cancer patients present with advanced stages of disease.
These patients frequently develop locoregional recurrences, distant metastasis and/or second primary tumors resulting in 5-years survival rates of less than 60% The development of novel anti-cancer agents to impr…
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Israel, ASHKELON
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Germany, FRANKFURT AM MAIN
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Netherlands, Nijmegen
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Germany, HAMBURG
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
